IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction

Nature Reviews Immunology

Volumn 15, Issue 12, 2015, Pages 771-783

  Jabri, Bana ^a   Abadie, Valérie ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 15 RECEPTOR ALPHA; PROTEIN BINDING;

CELIAC DISEASE; CELL MATURATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; GENE EXPRESSION; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TISSUE SPECIFICITY; BACTERIAL INFECTION; BIOLOGICAL MODEL; CD8+ T LYMPHOCYTE; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL;

BACTERIAL INFECTIONS; CD8-POSITIVE T-LYMPHOCYTES; CELIAC DISEASE; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; MODELS, IMMUNOLOGICAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TH1 CELLS;

EID: 84948712534     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3919     Document Type: Review

References (153)

1. Cousens, L. P. et al. Two roads diverged: interferon α/β-and interleukin 12-mediated pathways in promoting T cell interferon γ responses during viral infection. J. Exp. Med. 189, 1315-1328 (1999).
2. Taylor, G. A., Feng, C. G. & Sher, A. Control of IFN-γ-mediated host resistance to intracellular pathogens by immunity-related GTPases (p47 GTPases). Microbes Infect. 9, 1644-1651 (2007).
3. Valentine, L., Potts, R. & Premenko-Lanier, M. CD8+ T cell-derived IFN-γ prevents infection by a second heterologous virus. J. Immunol. 189, 5841-5848 (2012).
4. Antonelli, A., Ferrari, S. M., Corrado, A., Di Domenicantonio, A. & Fallahi, P. Autoimmune thyroid disorders. Autoimmun. Rev. 14, 174-180 (2015).
5. Jabri, B. & Sollid, L. M. Tissue-mediated control of immunopathology in coeliac disease. Nat. Rev. Immunol. 9, 858-870 (2009).
6. Walker, L. S. & von Herrath, M. CD4 T cell differentiation in type 1 diabetes. Clin. Exp. Immunol. http://dx. doi. org/10. 1111/cei. 12672 (2015).
7. Rochman, Y., Spolski, R. & Leonard, W. J. New insights into the regulation of T cells by γc family cytokines. Nat. Rev. Immunol. 9, 480-490 (2009).
8. Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595-601 (2006).
9. Bergamaschi, C. et al. Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum. Blood 120, e1-e8 (2012).
10. Mortier, E., Woo, T., Advincula, R., Gozalo, S. & Ma, A. IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J. Exp. Med. 205, 1213-1225 (2008).
11. Ota, N., Takase, M., Uchiyama, H., Olsen, S. K. & Kanagawa, O. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation. J. Immunol. 185, 6041-6048 (2010).
12. Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13-25 (2013).
13. Wuest, S. C. et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17, 604-609 (2011).
14. Mishra, A., Sullivan, L. & Caligiuri, M. A. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin. Cancer Res. 20, 2044-2050 (2014).
15. Colpitts, S. L. et al. Cutting edge: the role of IFN-α receptor and MyD88 signaling in induction of IL-15 expression in vivo. J. Immunol. 188, 2483-2487 (2012).
16. Zhou, R., Wei, H., Sun, R., Zhang, J. & Tian, Z. NKG2D recognition mediates Toll-like receptor 3 signaling-induced breakdown of epithelial homeostasis in the small intestines of mice. Proc. Natl Acad. Sci. USA 104, 7512-7515 (2007).
17. Abadie, V. & Jabri, B. IL-15: a central regulator of celiac disease immunopathology. Immunol. Rev. 260, 221-234 (2014).
18. Waldmann, T. A. The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J. Investig. Dermatol. Symp. Proc. 16, S28-S30 (2013).
19. Harada, S. et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 42, 1508-1516 (1999).
20. McInnes, I. B. et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 2, 175-182 (1996).
21. Vaknin-Dembinsky, A., Brass, S. D., Gandhi, R. & Weiner, H. L. Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS. J. Neuroimmunol. 195, 135-139 (2008).
22. Bouchaud, G. et al. Epidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. J. Exp. Med. 210, 2105-2117 (2013).
23. Villadsen, L. S. et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. 112, 1571-1580 (2003).
24. Aringer, M. et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 40, 876-881 (2001).
25. Robak, E. et al. Proinflammatory interferon-gamma-inducing monokines (interleukin-12, interleukin-18, interleukin-15)-serum profile in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 13, 364-368 (2002).
26. Chen, J. et al. Insulin-dependent diabetes induced by pancreatic β cell expression of IL-15 and IL-15Rα. Proc. Natl Acad. Sci. USA 110, 13534-13539 (2013).
27. Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253-261 (1993).
28. Willerford, D. M. et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
29. Mlecnik, B. et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl Med. 6, 228ra37 (2014).
30. Sheridan, B. S. & Lefrancois, L. Intraepithelial lymphocytes: to serve and protect. Curr. Gastroenterol. Rep. 12, 513-521 (2010).
31. Kalinski, P., Hilkens, C. M., Wierenga, E. A. & Kapsenberg, M. L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20, 561-567 (1999).
32. Forrester, J. V., Xu, H., Lambe, T. & Cornall, R. Immune privilege or privileged immunity? Mucosal Immunol. 1, 372-381 (2008).
33. Simpson, E. A historical perspective on immunological privilege. Immunol. Rev. 213, 12-22 (2006).
34. McKenna, K. C. & Kapp, J. A. Ocular immune privilege and CTL tolerance. Immunol. Res. 29, 103-112 (2004).
35. Weaver, C. T. & Hatton, R. D. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat. Rev. Immunol. 9, 883-889 (2009).
36. Iwata, M. et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21, 527-538 (2004).
37. Johansson-Lindbom, B. et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J. Exp. Med. 202, 1063-1073 (2005).
38. Mora, J. R. et al. Selective imprinting of gut-homing T cells by Peyers patch dendritic cells. Nature 424, 88-93 (2003).
39. Coombes, J. L. et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757-1764 (2007).
40. Mucida, D. et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256-260 (2007).
41. Sun, C. M. et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204, 1775-1785 (2007).
42. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
43. DePaolo, R. W. et al. A specific role for TLR1 in protective TH17 immunity during mucosal infection. J. Exp. Med. 209, 1437-1444 (2012).
44. Schenkel, J. M. & Masopust, D. Tissue-resident memory T cells. Immunity 41, 886-897 (2014).
45. Thome, J. J. & Farber, D. L. Emerging concepts in tissue-resident T cells: lessons from humans. Trends Immunol. 36, 428-435 (2015).
46. Deshpande, P. et al. IL-7-and IL-15-mediated TCR sensitization enables T cell responses to self-antigens. J. Immunol. 190, 1416-1423 (2013).
47. Liu, R. B. et al. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc. Natl Acad. Sci. USA 110, 8158-8163 (2013).
48. Roberts, A. I. et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. 167, 5527-5530 (2001).
49. Lang, K. S. et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11, 138-145 (2005).
50. de Kauwe, A. L. et al. Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells. J. Immunol. 182, 7440-7450 (2009).
51. DePaolo, R. W. et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 471, 220-224 (2011).
52. Kim, S. K., Schluns, K. S. & Lefrancois, L. Induction and visualization of mucosal memory CD8 T cells following systemic virus infection. J. Immunol. 163, 4125-4132 (1999).
53. Marietta, E. et al. A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J. Clin. Invest. 114, 1090-1097 (2004).
54. Husby, S. et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J. Pediatr. Gastroenterol. Nutr. 54, 136-160 (2012).
55. Setty, M. et al. Distinct and synergistic contributions of epithelial stress and adaptive immunity to functions of intraepithelial killer cells and active celiac disease. Gastroenterology 149, 681-691(2015).
56. Long, S. A., Buckner, J. H. & Greenbaum, C. J. IL-2 therapy in type 1 diabetes: Trials and tribulations. Clin. Immunol. 149, 324-331 (2013).
57. Ring, A. M. et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol. 13, 1187-1195 (2012).
58. Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771-780 (2000).
59. Imamichi, H., Sereti, I. & Lane, H. C. IL-15 acts as a potent inducer of CD4+CD25hi cells expressing FOXP3. Eur. J. Immunol. 38, 1621-1630 (2008).
60. Lin, S. J. et al. Expansion of regulatory T cells from umbilical cord blood and adult peripheral blood CD4+CD25+ T cells. Immunol. Res. 60, 105-111 (2014).
61. Litjens, N. H. et al. Allogeneic mature human dendritic cells generate superior alloreactive regulatory T cells in the presence of IL-15. J. Immunol. 194, 5282-5293 (2015).
62. Marshall, D., Sinclair, C., Tung, S. & Seddon, B. Differential requirement for IL-2 and IL-15 during bifurcated development of thymic regulatory T cells. J. Immunol. 193, 5525-5533 (2014).
63. Raynor, J. et al. IL-15 fosters age-driven regulatory T cell accrual in the face of declining IL-2 levels. Front. Immunol. 4, 161 (2013).
64. DCruz, L. M. & Klein, L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. 6, 1152-1159 (2005).
65. Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142-1151 (2005).
66. Maloy, K. J. & Powrie, F. Fueling regulation: IL-2 keeps CD4+ Treg cells fit. Nat. Immunol. 6, 1071-1072 (2005).
67. Cousens, L. P. et al. Two roads diverged: interferon α/β-and interleukin 12-mediated pathways in promoting T cell interferon γ responses during viral infection. J. Exp. Med. 189, 1315-1328 (1999).
68. Taylor, G. A., Feng, C. G. & Sher, A. Control of IFN-γ-mediated host resistance to intracellular pathogens by immunity-related GTPases (p47 GTPases). Microbes Infect. 9, 1644-1651 (2007).
69. Valentine, L., Potts, R. & Premenko-Lanier, M. CD8+ T cell-derived IFN-γ prevents infection by a second heterologous virus. J. Immunol. 189, 5841-5848 (2012).
70. Antonelli, A., Ferrari, S. M., Corrado, A., Di Domenicantonio, A. & Fallahi, P. Autoimmune thyroid disorders. Autoimmun. Rev. 14, 174-180 (2015).
71. Jabri, B. & Sollid, L. M. Tissue-mediated control of immunopathology in coeliac disease. Nat. Rev. Immunol. 9, 858-870 (2009).
72. Walker, L. S. & von Herrath, M. CD4 T cell differentiation in type 1 diabetes. Clin. Exp. Immunol. http://dx. doi. org/10. 1111/cei. 12672 (2015).
73. Rochman, Y., Spolski, R. & Leonard, W. J. New insights into the regulation of T cells by γc family cytokines. Nat. Rev. Immunol. 9, 480-490 (2009).
74. Waldmann, T. A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595-601 (2006).
75. Bergamaschi, C. et al. Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum. Blood 120, e1-e8 (2012).
76. Mortier, E., Woo, T., Advincula, R., Gozalo, S. & Ma, A. IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J. Exp. Med. 205, 1213-1225 (2008).
77. Ota, N., Takase, M., Uchiyama, H., Olsen, S. K. & Kanagawa, O. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation. J. Immunol. 185, 6041-6048 (2010).
78. Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13-25 (2013).
79. Wuest, S. C. et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 17, 604-609 (2011).
80. Mishra, A., Sullivan, L. & Caligiuri, M. A. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin. Cancer Res. 20, 2044-2050 (2014).
81. Colpitts, S. L. et al. Cutting edge: the role of IFN-α receptor and MyD88 signaling in induction of IL-15 expression in vivo. J. Immunol. 188, 2483-2487 (2012).
82. Zhou, R., Wei, H., Sun, R., Zhang, J. & Tian, Z. NKG2D recognition mediates Toll-like receptor 3 signaling-induced breakdown of epithelial homeostasis in the small intestines of mice. Proc. Natl Acad. Sci. USA 104, 7512-7515 (2007).
83. Abadie, V. & Jabri, B. IL-15: a central regulator of celiac disease immunopathology. Immunol. Rev. 260, 221-234 (2014).
84. Waldmann, T. A. The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J. Investig. Dermatol. Symp. Proc. 16, S28-S30 (2013).
85. Harada, S. et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 42, 1508-1516 (1999).
86. McInnes, I. B. et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 2, 175-182 (1996).
87. Vaknin-Dembinsky, A., Brass, S. D., Gandhi, R. & Weiner, H. L. Membrane bound IL-15 is increased on CD14 monocytes in early stages of MS. J. Neuroimmunol. 195, 135-139 (2008).
88. Bouchaud, G. et al. Epidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. J. Exp. Med. 210, 2105-2117 (2013).
89. Villadsen, L. S. et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. 112, 1571-1580 (2003).
90. Aringer, M. et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 40, 876-881 (2001).
91. Robak, E. et al. Proinflammatory interferon-gamma-inducing monokines (interleukin-12, interleukin-18, interleukin-15)-serum profile in patients with systemic lupus erythematosus. Eur. Cytokine Netw. 13, 364-368 (2002).
92. Chen, J. et al. Insulin-dependent diabetes induced by pancreatic β cell expression of IL-15 and IL-15Rα. Proc. Natl Acad. Sci. USA 110, 13534-13539 (2013).
93. Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253-261 (1993).
94. Willerford, D. M. et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
95. Mlecnik, B. et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl Med. 6, 228ra37 (2014).
96. Sheridan, B. S. & Lefrancois, L. Intraepithelial lymphocytes: to serve and protect. Curr. Gastroenterol. Rep. 12, 513-521 (2010).
97. Kalinski, P., Hilkens, C. M., Wierenga, E. A. & Kapsenberg, M. L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20, 561-567 (1999).
98. Forrester, J. V., Xu, H., Lambe, T. & Cornall, R. Immune privilege or privileged immunity? Mucosal Immunol. 1, 372-381 (2008).
99. Simpson, E. A historical perspective on immunological privilege. Immunol. Rev. 213, 12-22 (2006).
100. McKenna, K. C. & Kapp, J. A. Ocular immune privilege and CTL tolerance. Immunol. Res. 29, 103-112 (2004).
101. Weaver, C. T. & Hatton, R. D. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat. Rev. Immunol. 9, 883-889 (2009).
102. Iwata, M. et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21, 527-538 (2004).
103. Johansson-Lindbom, B. et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J. Exp. Med. 202, 1063-1073 (2005).
104. Mora, J. R. et al. Selective imprinting of gut-homing T cells by Peyers patch dendritic cells. Nature 424, 88-93 (2003).
105. Coombes, J. L. et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757-1764 (2007).
106. Mucida, D. et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256-260 (2007).
107. Sun, C. M. et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204, 1775-1785 (2007).
108. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
109. DePaolo, R. W. et al. A specific role for TLR1 in protective TH17 immunity during mucosal infection. J. Exp. Med. 209, 1437-1444 (2012).
110. Schenkel, J. M. & Masopust, D. Tissue-resident memory T cells. Immunity 41, 886-897 (2014).
111. Thome, J. J. & Farber, D. L. Emerging concepts in tissue-resident T cells: lessons from humans. Trends Immunol. 36, 428-435 (2015).
112. Deshpande, P. et al. IL-7-and IL-15-mediated TCR sensitization enables T cell responses to self-antigens. J. Immunol. 190, 1416-1423 (2013).
113. Liu, R. B. et al. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc. Natl Acad. Sci. USA 110, 8158-8163 (2013).
114. Roberts, A. I. et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. 167, 5527-5530 (2001).
115. Lang, K. S. et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11, 138-145 (2005).
116. de Kauwe, A. L. et al. Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells. J. Immunol. 182, 7440-7450 (2009).
117. DePaolo, R. W. et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 471, 220-224 (2011).
118. Kim, S. K., Schluns, K. S. & Lefrancois, L. Induction and visualization of mucosal memory CD8 T cells following systemic virus infection. J. Immunol. 163, 4125-4132 (1999).
119. Marietta, E. et al. A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice. J. Clin. Invest. 114, 1090-1097 (2004).
120. Husby, S. et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J. Pediatr. Gastroenterol. Nutr. 54, 136-160 (2012).
121. Setty, M. et al. Distinct and synergistic contributions of epithelial stress and adaptive immunity to functions of intraepithelial killer cells and active celiac disease. Gastroenterology 149, 681-691(2015).
122. Long, S. A., Buckner, J. H. & Greenbaum, C. J. IL-2 therapy in type 1 diabetes: Trials and tribulations. Clin. Immunol. 149, 324-331 (2013).
123. Ring, A. M. et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol. 13, 1187-1195 (2012).
124. Kennedy, M. K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771-780 (2000).
125. Imamichi, H., Sereti, I. & Lane, H. C. IL-15 acts as a potent inducer of CD4+CD25hi cells expressing FOXP3. Eur. J. Immunol. 38, 1621-1630 (2008).
126. Lin, S. J. et al. Expansion of regulatory T cells from umbilical cord blood and adult peripheral blood CD4+CD25+ T cells. Immunol. Res. 60, 105-111 (2014).
127. Litjens, N. H. et al. Allogeneic mature human dendritic cells generate superior alloreactive regulatory T cells in the presence of IL-15. J. Immunol. 194, 5282-5293 (2015).
128. Marshall, D., Sinclair, C., Tung, S. & Seddon, B. Differential requirement for IL-2 and IL-15 during bifurcated development of thymic regulatory T cells. J. Immunol. 193, 5525-5533 (2014).
129. Raynor, J. et al. IL-15 fosters age-driven regulatory T cell accrual in the face of declining IL-2 levels. Front. Immunol. 4, 161 (2013).
130. DCruz, L. M. & Klein, L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat. Immunol. 6, 1152-1159 (2005).
131. Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142-1151 (2005).
132. Maloy, K. J. & Powrie, F. Fueling regulation: IL-2 keeps CD4+ Treg cells fit. Nat. Immunol. 6, 1071-1072 (2005)
133. Nguyen, K. B. et al. Coordinated and distinct roles for IFN-αβ, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169, 4279-4287 (2002).
134. Sharif-Askari, E., Fawaz, L. M., Tran, P., Ahmad, A. & Menezes, J. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture. J. Natl Cancer Inst. 93, 1724-1732 (2001).
135. Lanier, L. L. Evolutionary struggles between NK cells and viruses. Nat. Rev. Immunol. 8, 259-268 (2008).
136. Losy, J., Niezgoda, A. & Zaremba, J. IL-15 is elevated in sera of patients with relapsing-remitting multiple sclerosis. Folia Neuropathol. 40, 151-153 (2002).
137. Allez, M. et al. CD4+NKG2D+ T cells in Crohns disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 132, 2346-2358 (2007).
138. Groh, V., Bruhl, A., El-Gabalawy, H., Nelson, J. L. & Spies, T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 100, 9452-9457 (2003).
139. de Menthon, M. et al. Excessive interleukin-15 transpresentation endows NKG2D+CD4+ T cells with innate-like capacity to lyse vascular endothelium in granulomatosis with polyangiitis (Wegeners). Arthritis Rheum. 63, 2116-2126 (2011).
140. Kuczynski, S. et al. IL-15 is elevated in serum patients with type 1 diabetes mellitus. Diabetes Res. Clin. Pract. 69, 231-236 (2005).
141. Malchow, S. et al. Aire-dependent thymic development of tumor-associated regulatory T cells. Science 339, 1219-1224 (2013).
142. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
143. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
144. Fridman, W. H. et al. Immune infiltration in human cancer: prognostic significance and disease control. Curr. Top. Microbiol. Immunol. 344, 1-24 (2011).
145. Rubinstein, M. P. et al. Converting IL-15 to a superagonist by binding to soluble IL-15Rα. Proc. Natl Acad. Sci. USA 103, 9166-9171 (2006).
146. Wong, H. C., Jeng, E. K. & Rhode, P. R. The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8 T cells into innate-like effector cells with antitumor activity. Oncoimmunology 2, e26442 (2013).
147. Maas, R. A., Dullens, H. F. & Den Otter, W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol. Immunother. 36, 141-148 (1993).
148. Theofilopoulos, A. N., Baccala, R., Beutler, B. & Kono, D. H. Type I interferons α/β in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307-336 (2005).
149. Hammad, H. & Lambrecht, B. N. Barrier epithelial cells and the control of type 2 immunity. Immunity 43, 29-40 (2015).
150. De Nitto, D., Monteleone, I., Franze, E., Pallone, F. & Monteleone, G. Involvement of interleukin-15 and interleukin-21, two γ-chain-related cytokines, in celiac disease. World J. Gastroenterol. 15, 4609-4614 (2009).
151. Spolski, R. & Leonard, W. J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26, 57-79 (2008).
152. Sutherland, A. P. et al. IL-21 promotes CD8+ CTL activity via the transcription factor T-bet. J. Immunol. 190, 3977-3984 (2013).
153. Umlauf, S. W. et al. Molecular regulation of the IL-2 gene: rheostatic control of the immune system. Immunol. Rev. 133, 177-197 (1993).